Radiological and clinical improvement in a patient with COVID-19 pneumonia postconvalescent plasma transfusion: A case report

Helali, Abeer Ahmed Al; Saeed, Ghufran; Elholiby, Tamer Ibrahim; Kukkady, Mohamed Ashfaque; Mazrouei, Safaa Saeed Al

doi:10.1016/j.radcr.2020.07.031

Cited by 6 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 2 weeks, she recovered and discharged. No AEs Al Helali AA et al [53] Abu Dhabi, UAE Case report 55y/M 300 ml – 9 days Severe illness There was a significant radiological and clinical improvement in a few days’ post CPT. No significant AEs were observed.…”

Section: Resultsmentioning

confidence: 93%

“…Following removing duplicates and screening of titles and abstracts, we evaluated 153 articles in full text. Among these, we found 45 relevant articles (4RCTs, 11 controlled NRSIs, 7 non-controlled NRSIs and 23 case reports) [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] . Extracted details are presented in Table 1 (RCTs, controlled NRSIs, and non-controlled NRSIs) and table 2 (case report(series)).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Wang

Huo

Dai

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Wang

Huo

Dai

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

“…Chest X-rays were obtained at admission on the ICU and after two days of treatment. Chest X-rays were evaluated using the CXR scoring system, which was specifically designed for semi-quantitative assessment of lung involvement in COVID-19 10,11 . In the CXR scoring system, six different lung zones are scored.…”

Section: Methodsmentioning

confidence: 99%

Mortality reduction in ICU-admitted COVID-19 patients in Suriname after treatment with convalescent plasma acquired via gravity filtration

Bihariesingh

Bansie

Fröberg

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Although convalescent plasma (CP) treatment is a potential therapeutic option for patients with COVID-19, there is a paucity of data from studies in low-resource settings. The efficacy and safety of CP therapy in intensive care unit (ICU) patients with COVID-19 in Suriname was evaluated. A novel gravity-based filtration method was used to obtain CP. The design was an open-label, multi-centre, non-randomized prospective clinical trial performed in two hospitals in Suriname, from June 2020, to December 2020. A pre-planned interim analysis is reported in 78 PCR-confirmed COVID-19 patients admitted to the ICU with severe or lifethreatening symptoms. CP in combination with standard treatment (n = 28) was compared to standard treatment alone (control) (n = 50), stratified by disease severity. The primary endpoint was 28-day ICU mortality. Secondary (exploratory) endpoints were changes two days after treatment initiation in pulmonary oxygen exchange capacity (PF ratio) and chest xray (CXR) score. Findings The median age of patients was 52 years with 43 [55.1%] being male. Twenty-eight day mortality occurred in 18% (5/28) of the CP group vs 36% (18/50) of the control group. Survival probability was significantly higher in the CP group compared to the control group with standard care (P=0.027). When stratifying into disease severity, the survival probability was the lowest for the control group with life-threatening disease (P=0.0051). CP treatment of severe COVID-19 resulted in a higher probability of survival, with a hazard ratio (HR) of 0.22 (95% CI, 0.074-0.067), correcting for age, the presence of diabetes and COVID-19 severity. Age significantly increased the mortality risk (HR, 1.08 [95%CI, 1.022-1.14]; P =0.006). In the severe group, CP resulted in an improved CXR score (P =0.0013) and increase in PF ratio (P = 0.011) as compared to standard therapy. The gravity-based plasmapheresis method used for CP production was well-tolerated and no adverse events were observed in the donors. Interpretation Among patients with severe or life-threatening COVID-19, CP therapy in combination with standard treatment resulted in 78% reduction of 28-day ICU mortality (HR = 0.22) compared to standard treatment alone. Both CXR-score and PF ratio changes represent indicators of treatment effect of CP after two days and can easily be implemented in low-resource settings. The novel CP production method was effective and represents a practical solution for low and middle income countries (LMICs) to produce CP locally. Although interpretation is limited by the non-randomised design of the trial, these results offer a potential route for broader implementation of CP treatment in LMICs.

show abstract

“…Chest x-rays were obtained at admission to ICU and after two days of treatment. Chest x-rays were evaluated using the CXR scoring system, which was specifically designed for semi-quantitative assessment of lung involvement in COVID-19 [10,11]. In the CXR scoring system, six different lung zones are scored.…”

Section: Data Collectionmentioning

confidence: 99%

Mortality Reduction in ICU-Admitted COVID-19 Patients in Suriname after Treatment with Convalescent Plasma Acquired Via Gravity Filtration

Bihariesingh¹,

Bansie²,

Fröberg³

et al. 2021

ACR

View full text Add to dashboard Cite

Introduction: Although convalescent plasma (CP) treatment is a potential therapeutic option for patients with COVID-19, there is a paucity of data from intensive care unit (ICU) patients with COVID-19 in low-resource settings, such as Suriname. CP was produced by a novel gravity-based filtration method. Methods: In an open-label, multi-center, non-randomized prospective clinical trial, patients with severe or life- threatening COVID-19 symptoms (n=28) with CP treatment were compared with standard treatment alone (n=50). A pre-planned interim analysis is reported. The primary endpoint was a 28-day ICU mortality. Secondary endpoints were changes two days after treatment initiation in pulmonary oxygen exchange capacity (PF ratio) and chest x-ray (CXR) score. Results: Mortality occurred in 18% (CP: 5/28) vs. 36% (Control:18/50). CP treatment of severe COVID-19 resulted in a higher probability of survival, with a hazard ratio (HR) of 0.22 (95% CI, 0.074-0.067), correcting for age, the presence of diabetes and COVID-19 severity. In the severe group, CP resulted in an improved CXR score (P = 0.0013) and increase in PF ratio (P = 0.011) as compared to standard therapy. The gravity-based plasmapheresis method used for CP production was well-tolerated and no adverse events were observed in the donors. Discussion: CP therapy in combination with standard treatment resulted in 78% reduction of 28-day ICU mortality (HR = 0.22) compared to standard treatment alone. Both CXR-score and PF ratio changes represent effective indicators for the treatment effect of CP after two days. The novel CP production method was effective and represents a practical solution for Low- and middle-income countries to produce CP.

show abstract

Radiological and clinical improvement in a patient with COVID-19 pneumonia postconvalescent plasma transfusion: A case report

Cited by 6 publications

References 9 publications

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Mortality reduction in ICU-admitted COVID-19 patients in Suriname after treatment with convalescent plasma acquired via gravity filtration

Mortality Reduction in ICU-Admitted COVID-19 Patients in Suriname after Treatment with Convalescent Plasma Acquired Via Gravity Filtration

Contact Info

Product

Resources

About